Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: A case-control study comparing colestimide with acarbose

Journal of Nippon Medical School

Volumn 73, Issue 5, 2006, Pages 277-284

  Suzuki, Tatsuya ^a,b   Oba, Kenzo ^a,b   Futami, Shoko ^a,b   Suzuki, Kazunari ^a,b   Ouchi, Motoshi ^a,b   Igari, Yoshimasa ^a,b   Matsumura, Noriaki ^a,b   Watanabe, Kentaro ^a,b   Kigawa, Yoshiaki ^a,b   Nakano, Hiroshi ^a,b  

^a NIPPON MEDICAL SCHOOL GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Acarbose; Colestimide; Glycemic control; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; COLESTILAN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; LIPID; PIOGLITAZONE; TOLBUTAMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ACARBOSE; AGED; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; EPICHLOROHYDRIN; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIC AGENTS; IMIDAZOLES; LIPIDS; MALE; RESINS, SYNTHETIC;

EID: 33750522053     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.73.277     Document Type: Article

References (22)

1. Homma Y, Kobayashi T, Yamaguchi H, et al.: Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in type II hyperlipoproteinemia. Atherosclerosis 1997; 129: 241-248.
2. Garg A, Grundy SM: Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus: A short-term, double-blind, crossover trial. Ann Internal Med 1994; 121: 416-422.
3. Jenkins DJ, Wolever TM, Leeds AR, et al.: Dietary fibres, fibre analogues, and glucose tolerance of viscosity. British Medical Journal 1978; 1: 1392-1394.
4. Waki M, Koh H, Nambu S: Cholestyramine improves glycemic control in diabetic patients. J Jpn Atheroscler Soc 1988; 15: 81581-81584.
5. Watanabe M, Houten SM, Mataki C, et al.: Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484-489.
6. Puls W, Keup U, Krause HP, Thomas G: Glucosidase inhibition: A new approach to the treatment of carbohydrate dependent metabolic disorders. Diabetologia 1977; 13: 426.
7. Caspary WF: Sucrose malabsorption in man after ingestion of alpha-glucosidase hydrolase inhibitor. Lancet 1978; 1: 1231-1233.
8. Wojcicki JM: J-Index.: A new proposition of the assessment of current glucose control in diabetic patients. Horm Metab Res 1995; 27: 41-42.
9. Schlichtkrull J, Munch O, Jersild M: The M-value, an index of blood sugar control in diabetics. Acta Med Scand 1965; 177: 95-102.
10. Wojcicki JM: Mathematical description of the glucose control in diabetes therapy. Analysis of the Schlichtkrull M-value. Horm Metab Res 1995; 27: 1-5.
11. Hansfeld M, Fisher S, Shultze J, et al.: Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991; 14: 732-737.
12. Kogire M, Gomez G, Uchida T, Ishizuka J, Greedley GH Jr, Thompson JC: Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats. Pancreas 1992; 7: 15-20.
13. Karlsson S, Ahren B: Cholecystokinin-stimulated insulin secretion and protein kinase C in rat pancreatic islets. Acta Physiol Scand 1991; 142: 397-403.
14. Ahren B, Martensson H, Nobin A: Cholecystokinin (CCK)-4 and CCK-8 stimulate islet hormones secretion in vivo in the pig. Pancreas 1988; 3: 279-284.
15. Kajiyama G, Mizuno T, Takizawa I, et al.: Effect of MCI-196 on billiary lipids metabolism in patients with hypercholesterolemia. J Clin Ther Med 1996; 12: 1349-1359.
16. Urger RH: Lipotoxity in the pathogenesis of obesity-dependent NIDDM; Genetic and clinical implications. Diabetes 1995; 44: 863-870.
17. Poitout V, Robertoson RP: Secondary β-cell failure in type 2 diabetes-A convergence of glucotoxicity and lipotoxicity. Endocrinology 2002; 143: 339-342.
18. Hashim SA, Bergen SS Jr, van Itallie TB: Experimental steatorrhea induced in man by bile acid sequestrant. Pro Soc Exp Biol Metab 1961; 106: 173-175.
19. Josse RG, Chiasson JL, Ryan EA, et al.: Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Research and Clinical Practice 2003; 59: 37-42.
20. Hwu CM, Ho LT, Fuh MMT, et al.: Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: Results from a multinational, placebo-controlled study. Diabetes Research and Clinical Practice 2003; 60: 111-118.
21. Hansson L, Hedner T, Dahlof B: Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Pressure 1992; 1: 113-119.
22. Hansson L, for the HOT Study Group: The Hypertension Optimal Treatment Study (the Hot Study): The Hypertension Optimal Treatment Study (The HOT Study). Blood Pressure 1993; 2: 62-68.